All Cosmos Bio-Tech Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

All Cosmos Bio-Tech Holding hat ein Gesamteigenkapital von NT$2.9B und eine Gesamtverschuldung von NT$555.0M, wodurch sich der Verschuldungsgrad auf 19.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen NT$3.8B bzw. NT$895.4M. All Cosmos Bio-Tech Holding Das EBIT des Unternehmens beträgt NT$154.1M, so dass der Zinsdeckungsgrad -4.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von NT$1.5B.

Wichtige Informationen

19.4%

Verhältnis von Schulden zu Eigenkapital

NT$555.01m

Verschuldung

Zinsdeckungsgrad	-4.3x
Bargeld	NT$1.51b
Eigenkapital	NT$2.86b
Gesamtverbindlichkeiten	NT$895.38m
Gesamtvermögen	NT$3.75b

Jüngste Berichte zur Finanzlage

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Apr 20

Recent updates

There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing Earnings

Mar 22

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Apr 20

Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting Picture

Jan 10

All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With Earnings

Dec 22

Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?

Dec 01

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 4148Die kurzfristigen Aktiva des Unternehmens (NT$2.8B) übersteigen seine kurzfristigen Passiva (NT$837.7M).

Langfristige Verbindlichkeiten: 4148Die kurzfristigen Vermögenswerte des Unternehmens (NT$2.8B) übersteigen seine langfristigen Verbindlichkeiten (NT$57.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 4148 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 4148Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 6.9% auf 19.4% gestiegen.

Schuldendeckung: 4148Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (89.5%).

Zinsdeckung: 4148 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

All Cosmos Bio-Tech Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Recent updates

All Cosmos Bio-Tech Holding Corporation to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: NT$0.12 (vs NT$0.61 in 2Q 2023)

All Cosmos Bio-Tech Holding Corporation to Report Q2, 2024 Results on Aug 27, 2024

Upcoming dividend of NT$1.00 per share

First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.63 in 1Q 2023)

Dividend of NT$1.00 announced

All Cosmos Bio-Tech Holding Corporation to Report Q1, 2024 Results on May 13, 2024

New minor risk - Market cap size

All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024

There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing Earnings

Full year 2023 earnings released: EPS: NT$2.18 (vs NT$5.75 in FY 2022)

All Cosmos Bio-Tech Holding Corporation Announces the Retirement of Ling Siu Hung as Chief Operating Officer

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$2.48 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.61 (vs NT$1.47 in 2Q 2022)

New minor risk - Market cap size

Upcoming dividend of NT$2.50 per share at 4.1% yield

Full year 2022 earnings released: EPS: NT$5.75 (vs NT$3.09 in FY 2021)

Investor sentiment improves as stock rises 16%

Third quarter 2022 earnings released: EPS: NT$2.48 (vs NT$0.76 in 3Q 2021)

High number of new directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: NT$1.47 (vs NT$0.66 in 2Q 2021)

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

All Cosmos Bio-Tech Holding Corporation Announces Change in Remuneration Committee

All Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021

Upcoming dividend of NT$1.50 per share

First quarter 2022 earnings released: EPS: NT$1.07 (vs NT$0.42 in 1Q 2021)

Investor sentiment deteriorated over the past week

Price target increased to NT$102

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: NT$3.09 (vs NT$1.28 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.54 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS NT$0.66 (vs NT$0.60 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.41 loss in 1Q 2020)

All Cosmos Bio-Tech Holding Corporation Announces Cash Dividend, Payable on July 30, 2021

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Price target decreased to NT$40.00

Acting for the Malaysian Subsidiary All Cosmos Bio-Tech Holding Corporation to Announce Temporary Shutdown of the Production Department

Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting Picture

New 90-day high: NT$39.40

All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With Earnings

Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?

Third quarter 2020 earnings released: EPS NT$0.54

New 90-day low: NT$33.80

First half earnings released

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen